Display options
Cite
Tannock IF, Booth CM, Gyawali B, et al. Radiographic progression-free survival in the ACIS trial for prostate cancer. Lancet Oncol. 2022;23(1):e4doi: 10.1016/S1470-2045(21)00719-1.
Tannock, I. F., Booth, C. M., Gyawali, B., & Joshua, A. M. (2022). Radiographic progression-free survival in the ACIS trial for prostate cancer. The Lancet. Oncology, 23(1), e4. https://doi.org/10.1016/S1470-2045(21)00719-1
Tannock, Ian F, et al. "Radiographic progression-free survival in the ACIS trial for prostate cancer." The Lancet. Oncology vol. 23,1 (2022): e4. doi: https://doi.org/10.1016/S1470-2045(21)00719-1
Tannock IF, Booth CM, Gyawali B, Joshua AM. Radiographic progression-free survival in the ACIS trial for prostate cancer. Lancet Oncol. 2022 Jan;23(1):e4. doi: 10.1016/S1470-2045(21)00719-1. PMID: 34973231.
Copy Download .nbib Format: NLM
Share it on

Lancet Oncol. 2022 Jan;23(1):e4. doi: 10.1016/S1470-2045(21)00719-1.

Radiographic progression-free survival in the ACIS trial for prostate cancer.

The Lancet. Oncology

Ian F Tannock, Christopher M Booth, Bishal Gyawali, Anthony M Joshua

Affiliations

  1. Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Electronic address: [email protected].
  2. Division of Cancer Care and Epidemiology, Department of Oncology, and Department of Public Health Sciences, Queen's University, Kingston, ON, Canada.
  3. Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.

PMID: 34973231 DOI: 10.1016/S1470-2045(21)00719-1

[No abstract available.]

Conflict of interest statement

We declare no competing interests.

Publication Types